SG11202002088TA - Methods and compositions for treating chronic lung diseases - Google Patents

Methods and compositions for treating chronic lung diseases

Info

Publication number
SG11202002088TA
SG11202002088TA SG11202002088TA SG11202002088TA SG11202002088TA SG 11202002088T A SG11202002088T A SG 11202002088TA SG 11202002088T A SG11202002088T A SG 11202002088TA SG 11202002088T A SG11202002088T A SG 11202002088TA SG 11202002088T A SG11202002088T A SG 11202002088TA
Authority
SG
Singapore
Prior art keywords
compositions
methods
treating chronic
lung diseases
chronic lung
Prior art date
Application number
SG11202002088TA
Other languages
English (en)
Inventor
Norman Barton
Alexandra Mangili
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of SG11202002088TA publication Critical patent/SG11202002088TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11202002088TA 2017-09-11 2018-09-11 Methods and compositions for treating chronic lung diseases SG11202002088TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762557113P 2017-09-11 2017-09-11
PCT/US2018/050427 WO2019051474A1 (en) 2017-09-11 2018-09-11 METHODS AND COMPOSITIONS FOR TREATING CHRONIC PULMONARY DISEASES

Publications (1)

Publication Number Publication Date
SG11202002088TA true SG11202002088TA (en) 2020-04-29

Family

ID=63794620

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002088TA SG11202002088TA (en) 2017-09-11 2018-09-11 Methods and compositions for treating chronic lung diseases

Country Status (25)

Country Link
US (3) US20190151411A1 (cg-RX-API-DMAC7.html)
EP (3) EP3681602B1 (cg-RX-API-DMAC7.html)
JP (3) JP7819893B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200097679A (cg-RX-API-DMAC7.html)
CN (1) CN111432881A (cg-RX-API-DMAC7.html)
AU (2) AU2018328827B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020004760A2 (cg-RX-API-DMAC7.html)
CA (1) CA3075482A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020000597A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020004244A2 (cg-RX-API-DMAC7.html)
DK (1) DK3681602T3 (cg-RX-API-DMAC7.html)
EA (1) EA202090705A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP20055797A (cg-RX-API-DMAC7.html)
ES (1) ES3075637T3 (cg-RX-API-DMAC7.html)
IL (1) IL273174B2 (cg-RX-API-DMAC7.html)
LT (1) LT3681602T (cg-RX-API-DMAC7.html)
MX (1) MX421623B (cg-RX-API-DMAC7.html)
MY (1) MY204825A (cg-RX-API-DMAC7.html)
PE (1) PE20201166A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020500489A1 (cg-RX-API-DMAC7.html)
PT (1) PT3681602T (cg-RX-API-DMAC7.html)
SG (1) SG11202002088TA (cg-RX-API-DMAC7.html)
UA (1) UA128690C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019051474A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202001568B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3681602B1 (en) 2017-09-11 2026-04-15 Oak Hill Bio Limited Compositions for reducing the incidence of bpd
KR20230113287A (ko) * 2020-10-19 2023-07-28 오크 힐 바이오 리미티드 신생아에 사용하기에 적합한 조성물
CA3248280A1 (en) * 2022-05-04 2023-11-09 Oak Hill Bio Limited POLYTHERAPY FOR PREMATURE INFANTS
WO2023242440A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
ATE90690T1 (de) 1987-04-06 1993-07-15 Celtrix Pharma Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung.
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ATE132164T1 (de) 1988-04-12 1996-01-15 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
EP0639981A4 (en) 1992-05-08 1995-06-28 Univ Jefferson ANALOGS OF THE IGF FACTOR (01/18/94).
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
EP0956041A1 (en) 1996-09-16 1999-11-17 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US20020028764A1 (en) 2000-09-04 2002-03-07 Aarhus Amt. Treatment of acute and chronic liver disease
CA2429615C (en) 2000-11-28 2016-07-12 Children's Medical Center Corporation Determination of risk and treatment of complications of prematurity
WO2004113382A1 (en) 2003-06-13 2004-12-29 Insmed, Inc. Recombinant igf expression systems
CA2899824A1 (en) 2004-12-24 2006-06-29 Insmed, Inc. Purified rhigf-i/rhigfbp-3 complexes and their method of manufacture
WO2008130315A1 (en) * 2007-04-18 2008-10-30 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity
RU2558821C2 (ru) 2009-11-17 2015-08-10 Ипсен Фарма С.А.С. ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1
US9168289B2 (en) 2011-02-01 2015-10-27 Mor Research Applications Ltd. Method of treatment of small for gestational age infants under two years of age
CA2897062A1 (en) 2013-01-15 2014-07-24 Teva Pharmaceutical Industries Ltd. Lyophilization process
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
EP3681602B1 (en) 2017-09-11 2026-04-15 Oak Hill Bio Limited Compositions for reducing the incidence of bpd

Also Published As

Publication number Publication date
CN111432881A (zh) 2020-07-17
AU2018328827B2 (en) 2024-07-25
IL273174B2 (en) 2024-12-01
MY204825A (en) 2024-09-18
CO2020004244A2 (es) 2020-05-29
CA3075482A1 (en) 2019-03-14
AU2024227601B2 (en) 2026-04-23
UA128690C2 (uk) 2024-10-02
MX421623B (es) 2025-03-14
JP2025114869A (ja) 2025-08-05
EP3681602B1 (en) 2026-04-15
ES3075637T3 (en) 2026-08-06
EP4663184A3 (en) 2026-03-18
US20220088132A1 (en) 2022-03-24
IL273174A (en) 2020-04-30
WO2019051474A1 (en) 2019-03-14
JP7819893B2 (ja) 2026-02-25
IL273174B1 (en) 2024-08-01
PH12020500489A1 (en) 2021-02-22
LT3681602T (lt) 2026-07-27
AU2024227601A1 (en) 2024-11-14
US20240415927A1 (en) 2024-12-19
EP4748372A2 (en) 2026-05-27
EP4748372A3 (en) 2026-08-05
KR20200097679A (ko) 2020-08-19
BR112020004760A2 (pt) 2020-09-15
AU2018328827A1 (en) 2020-04-02
JP2020533344A (ja) 2020-11-19
DK3681602T3 (da) 2026-06-29
JP2023145646A (ja) 2023-10-11
US12678482B2 (en) 2026-07-14
CL2020000597A1 (es) 2020-12-04
EP3681602A1 (en) 2020-07-22
ZA202001568B (en) 2023-09-27
PE20201166A1 (es) 2020-10-28
EP4663184A2 (en) 2025-12-17
EA202090705A1 (ru) 2020-06-11
ECSP20055797A (es) 2020-10-30
PT3681602T (pt) 2026-07-20
US20190151411A1 (en) 2019-05-23
MX2020002744A (es) 2020-10-01

Similar Documents

Publication Publication Date Title
IL304820A (en) Preparations and methods for the treatment of cancer
IL290150A (en) Compounds and methods for treating chronic pain
SG11201705093UA (en) Composition for treating il-6-related diseases
IL256523A (en) Compositions and methods for treating cancer
EP3139928A4 (en) Anordrin compositions and methods for treating diseases
EP3310385A4 (en) Methods and compositions for treating fibrotic diseases
EP3110446A4 (en) Methods and compositions for treating siglec-8 associated diseases
EP3285874A4 (en) Compositions and methods for treating mycobacteria infections and lung disease
SG10201913400QA (en) Methods for treating lung disorders
IL275767A (en) Compositions and methods for treating metabolic diseases
IL255638A (en) Compositions and methods for treating cancer
IL261010B (en) Compositions and methods for treating chronic wounds
ZA201605492B (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
IL255079A0 (en) Methods of treating lung cancer
ZA201802376B (en) Compositions and methods for treatment of homocystinuria
IL269743A (en) Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions
EP3262065A4 (en) Methods and compositions for treating dystroglycanopathy disorders
EP3273965A4 (en) Composition and methods for treating chronic kidney disease
IL272945A (en) Local preparations and methods of treatment
IL258512B (en) Methods and preparations for the prevention or treatment of cancer
EP3496696A4 (en) COMPOUNDS AND METHODS FOR TREATING THE DISEASE.
IL252707B (en) Compositions and methods for treating diseases
SG11201803080YA (en) Compositions and methods for immune-mediated cancer therapy
SG10201912086QA (en) Compositions and methods for treating cancer
HK40034244A (en) Methods and compositions for treating chronic lung diseases